Brain-Predicted Age Difference Moderates the Association Between Muscle Strength and Mobility
- PMID: 35173606
- PMCID: PMC8841783
- DOI: 10.3389/fnagi.2022.808022
Brain-Predicted Age Difference Moderates the Association Between Muscle Strength and Mobility
Abstract
Background: Approximately 35% of individuals over age 70 report difficulty with mobility. Muscle weakness has been demonstrated to be one contributor to mobility limitations in older adults. The purpose of this study was to examine the moderating effect of brain-predicted age difference (an index of biological brain age/health derived from structural neuroimaging) on the relationship between leg strength and mobility.
Methods: In community dwelling older adults (N = 57, 74.7 ± 6.93 years; 68% women), we assessed the relationship between isokinetic leg extensor strength and a composite measure of mobility [mobility battery assessment (MBA)] using partial Pearson correlations and multifactorial regression modeling. Brain predicted age (BPA) was calculated from T1 MR-images using a validated machine learning Gaussian Process regression model to explore the moderating effect of BPA difference (BPAD; BPA minus chronological age).
Results: Leg strength was significantly correlated with BPAD (r = -0.317, p < 0.05) and MBA score (r = 0.541, p < 0.001). Chronological age, sex, leg strength, and BPAD explained 63% of the variance in MBA performance (p < 0.001). BPAD was a significant moderator of the relationship between strength and MBA, accounting for 7.0% of MBA score variance [△R 2 = 0.044, F(1,51) = 6.83, p = 0.01]. Conditional moderation effects of BPAD indicate strength was a stronger predictor of mobility in those with a great BPAD.
Conclusion: The relationship between strength and mobility appears to be influenced by brain aging, with strength serving as a possible compensation for decline in neural integrity.
Keywords: brain aging; dynapenia; physical function; sarcopenia; weakness.
Copyright © 2022 Vaughan, Simon, Grooms, Clark, Wages and Clark.
Conflict of interest statement
In the past 5-years, BC has received research funding from NMD Pharma, Regeneron Pharmaceuticals, Astellas Pharma Global Development, Inc., and RTI Health Solutions for contracted studies that involved aging and neuromuscular related research. In the past 5-years, BC has received consulting fees from Regeneron Pharmaceuticals, Zev industries, and the Gerson Lehrman Group for consultation specific to age-related neuromuscular weakness. BC is a co-founder with equity of OsteoDx Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
Grants and funding
LinkOut - more resources
Full Text Sources
